Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Daily cadence·500 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 24 epsHosts
Recent guests
Recent episodes
S17 Ep36: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Michael J. Mauro, MD
Jun 22, 2026
9m 33s
S17 Ep35: KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD
Jun 19, 2026
10m 42s
S17 Ep34: As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD
Jun 18, 2026
13m 14s
S17 Ep33: Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer — What the Latest Data Really Tell Us
Jun 15, 2026
30m 45s
S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD
Jun 10, 2026
10m 21s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/22/26 |  S17 Ep36: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Michael J. Mauro, MD | In today’s episode, we spoke with Michael J. Mauro, MD, an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.In our exclusive interview, Dr Mauro discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA approval for patients with chronic myeloid leukemia (CML). After diving into the approval itself and the data that supported it, Mauro discussed why the approval is significant and which patients it will benefit most. In addition to covering the approval, Mauro shed light on what is to come for biosimilars and alternate formulations in the greater CML treatment paradigm. | 9m 33s | ||||||
| 6/19/26 |  S17 Ep35: KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD | In this episode of OncLive On Air, Zev A. Wainberg, MD, sat down with OncLive to discuss the rapidly evolving landscape of KRAS-directed therapy in pancreatic ductal adenocarcinoma (PDAC), from pan-RAS inhibition to KRAS G12D–specific strategies, and what the next several years of clinical investigation may look like for patients with this difficult-to-treat malignancy. Wainberg is a professor of medicine at the David Geffen School of Medicine at UCLA, co-director of the UCLA GI Oncology Program, and medical director of the UCLA Pancreas Cancer Center, where he also serves as director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center. This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive | 10m 42s | ||||||
| 6/18/26 |  S17 Ep34: As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD | In today’s episode, we welcomed Brad Haverkos, MD, to discuss evolving management and treatment adherence strategies in cutaneous T-cell lymphoma (CTCL). Dr Haverkos is an associate professor of medicine-hematology at the University of Colorado in Anschutz School of Medicine in Aurora. In the exclusive interview, Dr Haverkos outlined treatment approaches across early-stage and advanced CTCL, identified strategies for identifying disease progression in this patient population, and spoke about how clinicians manage mogamulizumab-kpkc (Poteligeo)-associated rash. | 13m 14s | ||||||
| 6/15/26 |  S17 Ep33: Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer — What the Latest Data Really Tell Us | In this podcast, experts Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Nadia Harbeck, MD; and Heather McArthur, MD, MPH; discuss updates from the SERENA-6, evERA, PREcoopERA, and TRAK-ER trials of oral selective estrogen receptor degraders (SERDS) in patients with hormone receptor–positive/HER2-negative (HR+/HER2–) early, advanced, and metastatic breast cancer (MBC). These results were presented at European Society for Molecular Oncology (ESMO) Breast 2026. | 30m 45s | ||||||
| 6/10/26 |  S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD✨ | multiple myelomaEHA Congress+3 | Joshua Richter, MD | Tisch Cancer InstituteBlavatnik Family-Chelsea Medical Center | New York, New YorkStockholm, Sweden | multiple myelomaEHA 2026+3 | — | 10m 21s | |
| 6/8/26 |  S17 Ep31: ASCO 2026 Plenary: RASolute 302✨ | oncologypancreatic cancer+3 | — | daraxonrasib (RMC-6236)Indiana University Health+1 | — | RASolute 302daraxonrasib+3 | — | 11m 27s | |
| 6/5/26 |  S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy✨ | molecular profilingglioma+4 | Manmeet Ahluwalia, MD, MBAAshley S. Margol, MD, MS | OncLive® On Air | — | gliomatargeted therapy+4 | — | 31m 56s | |
| 6/1/26 |  S17 Ep29: Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD✨ | radiation therapysystemic therapy+4 | Binh T. Ngo, MD | Keck School of Medicine of the University of Southern CaliforniaUSC Norris Comprehensive Cancer Center+1 | — | radiation oncologyskin cancer treatment+4 | — | 29m 32s | |
| 5/28/26 |  S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD✨ | molecular testingnon-small cell lung cancer+3 | Anthony Chi, MDMonica Peravali, MD+1 | Mid-Atlantic Permanente Medical GroupKaiser Permanente+1 | Maryland | molecular testingNGS+5 | — | 30m 12s | |
| 5/27/26 |  S17 Ep27: Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD✨ | cervical cancerimmunotherapy+4 | Meghan E. Shea, MD | pembrolizumabDana-Farber Cancer Institute+2 | Boston, Massachusetts | cervical cancerHPV vaccination+5 | — | 15m 34s | |
| 5/26/26 |  S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD✨ | small cell lung cancerimmunotherapy+3 | Jacob Sands, MDJacob Sands | tarlatamab-dlle (Imdelltra)rovalpituzumab tesirine (Rova-T)+2 | — | small cell lung cancerimmunotherapy+4 | — | 24m 59s | |
| 5/23/26 |  S17 Ep25: TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD✨ | TKIschronic myeloid leukemia+3 | Michael J. Mauro, MDMichael J. Mauro | dasatinibMemorial Sloan Kettering Cancer Center | New York | TKIsCML+5 | — | 16m 59s | |
| 5/20/26 |  S17 Ep24: Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD✨ | ESR1 mutation testingmetastatic breast cancer management+4 | Pedram Razavi, MD, PhDDara S. Ross, MD | camizestrantaromatase inhibitors+2 | — | ESR1 mutationsbreast cancer+6 | — | 37m 01s | |
| 5/13/26 |  S17 Ep22: Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD✨ | esophageal cancerdiagnosis+3 | Peter Enzinger, MDPeter Enzinger | zanidatamab-hrii (Ziihera)pembrolizumab (Keytruda)+3 | — | esophageal cancerdiagnosis+5 | — | 9m 36s | |
| 5/13/26 |  S17 Ep23: FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD✨ | FDA approvalbrexucabtagene autoleucel+4 | Luhua (Michael) Wang, MD | brexucabtagene autoleucelTecartus+1 | Houston | brexucabtagene autoleucelFDA approval+7 | — | 20m 46s | |
| 5/12/26 |  S17 Ep21: Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond✨ | breast cancersurvivorship+3 | Annie Bond | Tennessee Oncology | — | breast cancersurvivorship+5 | — | 48m 41s | |
| 5/8/26 |  S17 Ep20: Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD✨ | biomarker-directed therapiesgastrointestinal oncology+3 | Michael J. Pishvaian, MD, PhDMichael J. Pishvaian | zanidatamabJohns Hopkins Kimmel Cancer Center+1 | — | biomarkersGI oncology+3 | — | 22m 55s | |
| 5/6/26 |  S17 Ep19: Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer✨ | non-small cell lung cancerprecision care+3 | Sanja Dacic, MD, PhDIsabel Preeshagul, DO, MBS+1 | OncLive® On Air | — | non-small cell lung cancerpathology+3 | — | 30m 49s | |
| 5/4/26 |  S17 Ep18: Metastatic Bladder Cancer 2026 UPDATE✨ | metastatic bladder cancerurothelial carcinoma+4 | — | enfortumab vedotinpembrolizumab+2 | — | metastatic bladder cancerurothelial carcinoma+6 | — | 9m 20s | |
| 5/1/26 |  S17 Ep16: Show Me the Data®: From Mutation to Action—KRAS as a Therapeutic Target in PDAC✨ | KRAS-targeted therapiespancreatic cancer+3 | E. Gabriela Chiorean, MDTanios S. Bekaii-Saab, MD+2 | KRASPDAC+1 | — | KRAStherapeutic target+3 | — | 30m 12s | |
| 5/1/26 |  S17 Ep15: FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD✨ | breast cancerFES-PET/CT+3 | Megan Kruse, MD | National Comprehensive Cancer NetworkFES-PET/CT+2 | — | FES-PET/CTlobular breast cancer+3 | — | 15m 34s | |
| 4/30/26 |  S17 Ep14: Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD✨ | small cell lung cancertreatment advances+3 | Alissa Cooper, MDAlissa Cooper | tarlatamab-dlleImdelltra+4 | Boston, Massachusetts | SCLCFDA approval+3 | — | 27m 01s | |
| 4/30/26 |  S17 Ep13: Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer✨ | ctDNAbreast cancer+4 | Neil Iyengar, MDKelly Elizabeth McCann, MD, PhD+1 | OncLive® On Air | — | circulating tumor DNActDNA testing+3 | — | 25m 59s | |
| 4/30/26 |  S17 Ep12: ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD✨ | breast cancertriple-negative breast cancer+3 | Irene Morae Kang, MD | Tennessee OncologyCity of Hope Orange County | NashvilleIrvine, California | triple-negative breast cancerimmunotherapy+3 | — | 47m 23s | |
| 4/29/26 |  S17 Ep11: Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas✨ | neuroendocrine neoplasmsdiagnosis+4 | David S. Klimstra, MDDanielle A. Hutchings, MD+2 | — | — | neuroendocrine carcinomasdiagnostic dilemmas+3 | — | 31m 38s | |
Showing 25 of 500
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.